Tazorac en es it fr

Tazorac Brand names, Tazorac Analogs

Tazorac Brand Names Mixture

  • No information avaliable

Tazorac Chemical_Formula


Tazorac RX_link


Tazorac fda sheet

Tazorac FDA

Tazorac msds (material safety sheet)

Tazorac MSDS

Tazorac Synthesis Reference

No information avaliable

Tazorac Molecular Weight

263.786 g/mol

Tazorac Melting Point

No information avaliable

Tazorac H2O Solubility

Freely soluble

Tazorac State


Tazorac LogP


Tazorac Dosage Forms

Tablets (for oral administration, containing 250 mg of ticlopidine hydrochloride)

Tazorac Indication

Used to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke.

Tazorac Pharmacology

Ticlopidine is a platelet aggregation inhibitor structurally and pharmacologically similar to clopidogrel. When taken orally, ticlopidine causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. The intact drug has no significant in vitro activity at the concentrations attained in vivo; and, although analysis of urine and plasma indicates at least 20 metabolites, no metabolite which accounts for the activity of ticlopidine has been isolated.

Tazorac Absorption

Absorption is greater than 80%. Food increases absorption.

Tazorac side effects and Toxicity

Single oral doses of ticlopidine at 1600 mg/kg and 500 mg/kg were lethal to rats and mice, respectively. Symptoms of acute toxicity were GI hemorrhage, convulsions, hypothermia, dyspnea, loss of equilibrium and abnormal gait.

Tazorac Patient Information

Tazorac Organisms Affected

Humans and other mammals